French Glendon E. III sold $87K of LUNG

French Glendon E. III (President and CEO) sold 56,149 shares of Pulmonx Corp (LUNG) at an average of $1.55 ($1.54–$1.57) across 3 trades over 2026-06-01 to 2026-06-02.

Original reporting
SEC EDGAR · French Glendon E. III
Published Jun 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The modest insider sell may trigger short‑term price softness but is unlikely to affect long‑term fundamentals.

02

Market read

Provides fresh insider transaction data for traders monitoring LUNG.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions; this filing reports a recent sale by Pulmonx's CEO.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

President and CEO Glendon E. French III sold 56,149 shares for $86,874.79 in a Form 4 filing.

Expected impact

likely slight downward pressure as investors interpret the CEO's sell as a weak signal

Evidence & confidence

The sale size (~$87k) is small relative to market cap, but insider sales by a CEO are closely watched and can prompt short-term price dips.

Market effects

Minimal impact on the broader medical device sector; the transaction is company‑specific.

Negligible effect on regional markets.

None

Counterpoint

The sale could be a routine liquidity move and not indicative of future performance.

Key entities

  • Pulmonx Corp

    Medical device company listed on NASDAQ under ticker LUNG.

  • Glendon E. French III

    President and CEO of Pulmonx Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.